Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-iNKT cells with PD1 deletion
- Development stage
- Preclinical
- Lead developer
- SPH Biotherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-iNKT cells with PD1 deletion is an allogeneic, "off-the-shelf" cell therapy candidate developed by SPH Biotherapeutics for the treatment of relapsed/refractory multiple myeloma (R/R MM). The therapy utilizes invariant natural killer T (iNKT) cells, which express both an invariant T-cell receptor (TCR) and natural killer (NK) receptors, allowing for activation via lipid antigens (CD1d) and stress ligands without causing graft-versus-host disease (GvHD). These cells are engineered with a VHH-based chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA) and incorporate a proprietary PD-1 intracellular retention technology—a non-gene editing technique—to eliminate surface PD-1 expression. This modification is designed to enhance anti-tumor efficacy and overcome cell exhaustion within the immunosuppressive tumor microenvironment.
- Other names
- allogeneic BCMA CAR-expressing iNKT cells with PD1 deletionPD1-deleted iNKT product targeting BCMAPD-1-deleted iNKT product targeting BCMAPD 1-deleted iNKT product targeting BCMA
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-iNKT cells with PD1 deletion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-iNKT cells with PD1 deletion.